TrialJournal of diabetes investigation2018

Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance.

Sachiko HattoriPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.